Home > > > Personalized Immunotherapy for Autoimmune Diseases Market 2026 Sales Industry and Forecast till 2035

Personalized Immunotherapy for Autoimmune Diseases Market 2026 Sales Industry and Forecast till 2035

Author : vinayak sargar | Published On : 05 Mar 2026

Here are company-referenced insights with quantitative values for the Personalized Immunotherapy for Autoimmune Diseases Market (useful for market research or report writing).

Personalized Immunotherapy for Autoimmune Diseases Market

1. Recent Developments

  • Eli Lilly and Company + Repertoire Immune Medicines (2026) signed a collaboration worth up to USD 1.93 billion to develop personalized immune therapies targeting T-cell mechanisms in autoimmune diseases.

  • UCB partnered with Antengene (2026) for autoimmune candidate ATG-201, including USD 60 million upfront and up to USD 1.1 billion milestones.

  • Kyverna Therapeutics is advancing KYV-101 CAR-T therapy targeting stiff person syndrome, lupus nephritis, and myasthenia gravis, with Phase II trial milestones expected in 2025–2026.

https://www.thebrainyinsights.com/enquiry/sample-request/14851

2. Drivers (with company references)

  • Growing prevalence of autoimmune diseases (affecting ~5–10% of the global population) drives demand for targeted therapies.

  • Precision medicine platforms

    • BioNTech uses mRNA-based immunotherapy platforms to design personalized immune treatments.

  • Advances in cell & gene therapy

    • Cellectis develops gene-edited CAR-T cells using TALEN genome engineering.

  • Rising R&D investment

    • Strategic deals exceeding USD 1–2 billion between pharma and biotech firms highlight strong funding momentum.

3. Restraints

  • High therapy costs

    • Personalized cell therapies can exceed USD 300,000–500,000 per patient in advanced immunotherapies.

  • Manufacturing complexity

    • Autologous cell therapy production requires specialized facilities.

  • Regulatory hurdles

    • Safety concerns like cytokine release syndrome in CAR-T therapies.

  • Limited long-term clinical data for autoimmune indications.

Companies facing these issues include:

  • Allogene Therapeutics

  • CRISPR Therapeutics

  • Fate Therapeutics

4. Regional Segmentation Analysis

North America (≈40–45% market share)

  • Strong presence of biotech firms such as

    • IFM Therapeutics

    • Repertoire Immune Medicines

Europe (≈25–30%)

  • Key innovators

    • BioNTech (Germany)

    • Cellectis (France)

Asia-Pacific (≈20–25%)

  • Increasing clinical trials and biotech funding

  • Emerging companies and collaborations in China, Japan, and India.

Rest of the World (≈5–10%)

  • Growing adoption of biologics and biosimilars.

5. Emerging Trends

  • CAR-T therapy for autoimmune diseases

    • Example: Kyverna Therapeutics CD19-targeted CAR-T therapy.

  • Gene-editing technologies

    • CRISPR-based immune cell engineering.

  • mRNA-based immune modulation

    • Platforms developed by BioNTech.

  • AI-driven immune target discovery for personalized therapy development.

6. Top Use Cases

  1. Systemic Lupus Erythematosus (SLE)

  2. Rheumatoid Arthritis

  3. Multiple Sclerosis

  4. Myasthenia Gravis

  5. Inflammatory Bowel Disease

  6. Stiff Person Syndrome

Example:

  • Kyverna Therapeutics targeting lupus nephritis and SPS via CAR-T therapy.

7. Major Challenges

  • Manufacturing scalability

  • Immune-related toxicity

  • Patient-specific therapy logistics

  • Complex clinical trials

Companies addressing these challenges:

  • Cellectis (gene editing)

  • Fate Therapeutics (iPSC-derived immune cells)

8. Attractive Opportunities

  • Expansion of CAR-T therapies to autoimmune diseases

  • AI-driven drug discovery platforms

  • Off-the-shelf allogeneic immune cell therapies

  • Strategic pharma-biotech collaborations exceeding USD 1B deals

Example:

  • Eli Lilly and Company partnership worth USD 1.93 B for autoimmune immunotherapies.

9. Key Factors of Market Expansion

  • Increasing global autoimmune disease prevalence

  • Growth of precision medicine and genomic sequencing

  • Rising pharmaceutical R&D investments

  • Advancements in gene editing and CAR-T platforms

  • Strong strategic collaborations between biotech and pharma companies

Key companies contributing to expansion:

  • BioNTech

  • Cellectis

  • Allogene Therapeutics

  • CRISPR Therapeutics

✅ If you want, I can also provide:

  • 10 major companies with market share for this market

  • market size (2024–2035) with CAGR

  • a ready-to-use report-style paragraph format for each section.